Antengene (德琪医药, 6996.HK) is a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene has industry-leading R&D capabilities and differentiated strategic approach to developing novel oncology therapies. Antengene was listed on the Main Board of The Stock Exchange on 20th November 2020.
Founded in 2017, GenFleet Therapeutics (劲方医药) has established its proprietary R&D platform based on the deep understanding of disease biology, translational medicine, as well as the research into latest biological mechanism of cancer pathways, tumor micro-environment and human immunoregulation. GenFleet’s rich and diversified pipeline includes over 10 programs in development, many of which have entered clinical stages.
Hisoar Pharmaceuticals (海翔药业, 002009.SZ) is a leading manufacturer of API, pharma preparation, fine chemicals, dye and dye intermediates. Its parent company is DanKong Group, a Zhejiang Taizhou based conglomerate. Hisoar was listed on SZEX in 2006.
Ringene Biopharma (凌达生物) is a R&D driven pharmaceutical company focused on RTK-MAPK pathway related drug discovery and development. Ringene Biopharma has finished serie-A in Sep 2020 and is rapidly advancing its rich pipeline towards clinical trial.
Novoprotein (近岸蛋白质) is a leading recombinant protein R&D company. It has established a service platform for protein R&D, molecular evolution, antibody development, diagnostic, vaccine and drug development, which provides powerful support from protein manufacturing through end-use application.
(昂胜医疗) A preclinical stage startup incubated and funded by the CBC, ENSEM focuses on high value and difficult-to-drug oncology targets with significant unmet medical needs. Its mission is to discover, develop, and commercialize transformative oncology therapies while leading the advancement of AI-driven structural ensemble and computational drug design.
NiKang Therapeutics(霖康药业)is an US-based early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. NiKang is also funded by CBC.
Jugean is a small pharmaceutical supply chain company.
